Ernexa Therapeutics Inc. (NasdaqCM: ERNA)
Health Care · Biotechnology · US
$4.97
+2.26% today · -86.4% 1Y
Ernexa Therapeutics Inc. (NasdaqCM: ERNA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.93M and employs 5 people.
Over the last twelve months the share price has lost 86.4%, trading between 3.18 and 71.50.
Tweenvest scores Ernexa Therapeutics Inc. across four factors: quality 26/100. Its strongest factor is quality.
ERNA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.93M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -18.60
- Dividend yield
- —
- Beta (5Y)
- 2.56
- 52-week high
- $71.50
- 52-week low
- $3.18
- Avg volume (3M)
- —
- Shares outstanding
- 1.63M
- Employees
- 5
- Next earnings
- —
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
- ISIN
- US1140824079
- Founded
- 2018
- Listed since
- Aug 29, 1991
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.18 | +0.63% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.43 | +0.13% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.80 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.22 | +1.21% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.53 | +0.85% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.58 | +13.46% |
Figures last refreshed Aug 18, 2026.